Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indacaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 10/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | SRSF6 | Q13247 | 1/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indacaterol SCHEMBL29350045 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4186345 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29798949 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL48098 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL159597 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL867571 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL3664612 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4012030 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL867570 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4012026 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4093205-A1 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | KNOW Bio, LLC (US) | 2022-11-30 | — | — | EP | claimed |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026041802-A1 | AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF INFECTIONS | EPIENDO PHARMACEUTICALS EHF (IS) | 2026-02-26 | — | — | WO | disclosed |
| US-20260048050-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | Altesa BioSciences, Inc. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4683942-A1 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ADMINISTERING AN IL-4R ANTAGONIST | Sanofi Biotechnology (FR) | 2026-01-28 | — | — | EP | disclosed |
| EP-4683641-A1 | AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF EOSINOPHIL-RELATED DISEASES | EpiEndo Pharmaceuticals ehf. (IS) | 2026-01-28 | — | — | EP | disclosed |
| US-12533095-B1 | Airway mucus scoring system | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-27 | — | — | US | disclosed |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | GENENTECH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388685-A1 | METHODS FOR TREATING CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST | SANOFI BIOTECHNOLOGY (FR) | 2025-12-25 | — | — | US | disclosed |
| EP-3986901-A1 | PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986899-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986900-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-20220106322-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220106349-A1 | Compounds | EPIENDO PHARMACEUTICALS EHF (IS) | 2022-04-07 | — | — | US | disclosed |
| CN-114230571-A | Solid forms of isoquinolinones, methods of making, compositions containing, and methods of use thereof | 无限药品股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | disclosed |
| EP-3963055-A1 | VECTORIZED ANTIBODIES (VAB) AND USES THEREOF | Voyager Therapeutics, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3964507-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11236120-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | EPIENDO PHARMACEUTICALS EHF (IS) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106322-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | JAK2, JAK1, JAK3 | ADRB2 4470/4885ADRB1 4366/4885SLC6A2 4690/4885 |
| US-20220106349-A1 | Compounds | CFTR, AQP1, CTSA | ADRB2 4458/4885ADRB1 4506/4885SLC6A2 4248/4885 |
| US-20250388685-A1 | METHODS FOR TREATING CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST | IL4, CCR4, IL1RN | ADRB2 1412/4885ADRB1 1658/4885SLC6A2 4438/4885 |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | ADRB2 572/4885ADRB1 712/4885SLC6A2 1603/4885 |
| US-11236120-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | CFTR, AQP1, CTSA | ADRB2 4036/4885ADRB1 3857/4885SLC6A2 4163/4885 |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | ADRB2 2752/4885ADRB1 2044/4885SLC6A2 4574/4885 |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | JAK1, JAK2, CNKSR1 | ADRB2 560/4885ADRB1 226/4885SLC6A2 3995/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | ADRB2 1401/4885ADRB1 653/4885SLC6A2 4575/4885 |
| US-20260048050-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | RPP30, EXOSC9, RPL30 | ADRB2 636/4885ADRB1 385/4885SLC6A2 819/4885 |
| US-12533095-B1 | Airway mucus scoring system | MUC1, IL5, CYSLTR2 | ADRB2 306/4885ADRB1 587/4885SLC6A2 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.